Boehringer Ingelheim
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease SPIRIVA RESPIMAT (tiotropium bromide) is indicated for the long-term, once-daily, maintenance tr eatment of …
Download Boehringer Ingelheim
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION o …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for
MEDICATION GUIDE PRADAXA (pra dax a) …
docs.boehringer-ingelheim.com(dabigatran etexilate mesylate) capsules Read this Medication Guide before you start taking PRADAXA and each time you get a refill. There may be new
DOSAGE FORMS AND STRENGTHS------------------ …
docs.boehringer-ingelheim.comPage 2 of 28 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Parkinson's Disease MIRAPEX tablets are indicated for the treatment of …
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
docs.boehringer-ingelheim.comFULL PRESCRIBING INFORMATION WARNING: ASTHMA-RELATED DEATH Long-acting beta2-adrenergic agonists (LABA) such as olodaterol, one of the active ingredients in STIOLTO RESPIMAT, increase the risk of asthma-related
HIGHLIGHTS OF PRESCRIBING INFORMATION …
docs.boehringer-ingelheim.com2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). 2 DOSAGE AND ADMINISTRATION
HIGHLIGHTS OF PRESCRIBING INFORMATION …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA HANDIHALER safely and effectively.
MICARDIS -----------------------WARNINGS AND …
docs.boehringer-ingelheim.comControl of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management,
HIGHLIGHTS OF PRESCRIBING INFORMATION …
docs.boehringer-ingelheim.comFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer
HIGHLIGHTS OF PRESCRIBING INFORMATION Before initiating ...
docs.boehringer-ingelheim.com3 for volume contraction and correct volume status if indicated. Monitor for signs and symptoms of hypotension after initiating therapy and increase monitoring in clinical situations where volume contraction is expected [see Use in Specific Populations (8.5)].
PredniSONE Tablets USP, 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg ...
docs.boehringer-ingelheim.comacute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. ... Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during and after the stressful situation.
Related documents
HIGHLIGHTS OF PRESCRIBING ... - Boehringer Ingelheim
docs.boehringer-ingelheim.com150 mg capsules: brown, opaque, oblong, soft capsules imprinted in black with the Boehringer Ingelheim company symbol and "150". 100 mg capsules: peach, opaque, oblong, soft capsules imprinted in black with the Boehringer Ingelheim company symbol and "100". 4 CONTRAINDICATIONS None 5 WARNINGS AND PRECAUTIONS 5.1 Hepatic Impairment
HIGHLIGHTS OF PRESCRIBING ... - Boehringer Ingelheim
docs.boehringer-ingelheim.com3 full prescribing information warning: (a) premature discontinuation of pradaxa increases the risk of thrombotic events, and (b) spinal/epidural hematoma
Practice Parameters for Clinical Use of the Multiple Sleep ...
aasm.orgGlaxoSmithKline, Boehringer-Ingelheim, and Novartis; and is or has recently been a consultant for GlaxoSmithKline, Astrazeneca, Pfizer, Novartis, Boehringer-Ingelheim, Otsuka. Dr. Hirshkowitz is a member of the speakers’ bureau for Sanofi and Cephalon; and has received hono-raria from Sanofi and Cephalon. Dr. Bailey is a partner in Dental
PredniSONE Tablets USP, 1 mg, 2.5 ... - Boehringer Ingelheim
docs.boehringer-ingelheim.comC 21 H 26 O 5 M.W. 358.43 Prednisone is a white to practically white, odorless, crystalline powder. It is very slightly soluble in water; slightly soluble in …
Clinical Trial Protocol
www.clinicaltrials.govBoehringer Ingelheim Name of finished product: Not applicable Name of active ingredient: BIBF 1120 (nintedanib) Protocol date: Trial number: Revision date: 27 Jan 2012 1199.33 28 Mar 2017 Title of trial: An open-label extension trial of the long term safety oforal BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Co-ordinating ...
Assessment report - European Medicines Agency
www.ema.europa.euBoehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173 55216 Ingelheim am Rhein Germany 1.3. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP: Rapporteur: Pieter de Graeff Co-Rapporteur: Bart Van der Schueren • The application was received by the EMA on 5 March 2013.